| Document |
Document Title |
|
WO/2015/097605A1 |
The present disclosure relates to processes for the preparation of sofosbuvir or of its pharmaceutically acceptable salts. The present disclosure also provides intermediates useful in the synthesis of sofosbuvir.
|
|
WO/2015/099989A1 |
Crystalline solid forms of the anti-HCV compound (S)-isopropyl 2-((S)-(((2R,3R,4R,5R)- 5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-4-fluoro-3-hydro
xy-4- methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)
propanoate (Compound I...
|
|
WO/2015/095419A1 |
Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be admi...
|
|
WO/2015/095305A1 |
Provided herein are methods for the production of cyclic phosphate, cyclic phosphoramidate, cyclic thiophosphate, and cyclic phosphonate nucleoside compounds. Also provided herein are compounds useful in the production of cyclic phosphat...
|
|
WO/2015/085497A1 |
The present invention provides novel processes for the preparation of regadenoson having the formula (I). In some embodiments, the intermediates for the synthesis of regadenoson are also provided.
|
|
WO/2015/081867A1 |
The present invention provides a gemcitabine derivative of formula (I) and a method for preparing the same. The present invention further relates to a pharmaceutical composition comprising a pharmaceutically effective dose of the gemcita...
|
|
WO/2015/081297A1 |
Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be admi...
|
|
WO/2015/081133A2 |
Provided herein are compounds, compositions and methods for the treatment of liver cancer such as hepatocellular carcinoma, cholangiocarcinoma, or biliary tract cancer. In certain embodiments, compounds and compositions of nucleoside der...
|
|
WO/2015/077966A1 |
Provided are crystalline forms of the compound of formula (I), which is a nucleoside inhibitor of HCV, processes for the preparation thereof, and pharmaceutical compositions comprising these crystalline forms.
|
|
WO/2015/077292A1 |
Described herein are 5-position modified cytosine nucleotides and nucleosides as well as phosphoramidites and triphosphates derivatives thereof. Further provided are methods of making and using the same, and compositions and uses of the ...
|
|
WO/2015/077368A1 |
The present invention regards nucleoside 5'-monophosphate compounds of Formula I, their preparation and their uses. In some embodiments, such compounds are useful to treat hepatitis C viral infections.
|
|
WO/2015/073706A1 |
The present invention relates to DOT1L inhibitors. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating disorders in which DOT1-mediated protein methylation plays a part, su...
|
|
WO/2015/065661A1 |
Methods for removing 1,3,5-trimethylhexahydro-1,3,5-triazine and N-methylenemethanamine from a N-methylimidazole and methods for making oligonucleotides using N-methylimidazole are provided. In one embodiment, a method for removing 1,3,5...
|
|
WO/2015/066370A1 |
Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be admi...
|
|
WO/2015/066382A1 |
Compositions containing nicotinamide riboside (NR) are provided. NR containing compositions are used in the care or treatment of skin and skin conditions. In some embodiments, the invention relates to pharmaceutical compositions and cosm...
|
|
WO/2015/066162A1 |
The present invention relates to methods and intermediates for synthesizing 2'-deoxy-2',2'-difluorotetrahydrouridine compounds.
|
|
WO/2015/065956A1 |
The present invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof.
|
|
WO/2015/064718A1 |
Provided is a means for preventing inactivation of a photoresponsive nucleic acid probe by suppressing formation of photocrosslinking between a photoresponsive base having a photocrosslinkable vinyl structure and a photocrosslinkable thy...
|
|
WO/2015/066001A1 |
Methods and compositions are provided for identifying novel ligands for a protein target.
|
|
WO/2015/064223A1 |
This nucleotide derivative or a salt thereof is represented by one of formulae (I-1) to (I-6). (In formulae (I-1) to (I-6), R1-R5, A1-A3, B, X, Y and k represent the meanings set forth in claim 1.)
|
|
WO/2015/061507A1 |
This invention is related to nucleic acid chemistry and describes novel 1,2- dithiolane functionalized nucleoside phosphoramidites (1, Chart 1) and corresponding solid supports (2, Chart 1). In addition to these derivatives, 1,2- dithiol...
|
|
WO/2015/061683A1 |
Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be admi...
|
|
WO/2015/056213A1 |
The invention provides compounds of the formula (I) wherein B is a nucleobase selected from the groups (a) to (d): and the other variables are as defined in the claims, which are of use in the treatment or prophylaxis of hepatitis C viru...
|
|
WO/2014/052896A9 |
This disclosure relates to the use of uridine diphosphate (UDP) derivatives, salts and/or prodrugs thereof for the treatment of inflammatory conditions (e.g., psoriasis) and glaucoma, to prodrugs of UDP derivatives, compositions comprisi...
|
|
WO/2015/054465A1 |
Disclosed herein are nucleosides, nucleotides and nucleotide analogs, methods of synthesizing the same and methods of treating diseases and/or conditions such as a Picornavirus and/or Flaviviridae infection with one or more nucleosides, ...
|
|
WO/2015/050467A1 |
The subject matter of the invention is novel 2',3'-dideoxy-5-fluorouridine derivatives of general formula 1. wherein: R1 denotes cinchona alkaloid fragment with defined absolute configuration at C-8 and C-9 atoms. In the second aspect, t...
|
|
WO/2015/051169A2 |
The present disclosure provides alternative sugar moieties and polynucleotides comprising such sugar moieties, and methods of use thereof.
|
|
WO/2015/050468A1 |
The subject matter of the invention is novel 2,3'-anhydro-2'-deoxy-5-fluorouridine derivatives of general formula (1) where R is a trifluoromethyl, 2,2,2-trifluoroethyl, difluoromethyl, perfluoroethyl, 1-fluoroethyl, 2-fluoroethyl, 1,1-d...
|
|
WO/2015/051239A1 |
Described are methods of treating a subject after acute trauma to the head, viral encephalitis, or other causes of acute neurodegeneration, and/or after acute vascular insults, including ischemic and hemorrhagic strokes, the method compr...
|
|
WO/2014/178082A9 |
The present invention provides novel chiral serinyl functionalized tethered oligonucleotides i.e. R/S serinyl functionalized tethered oligonucleotides and the process of preparation thereof. Specifically, the present invention provides a...
|
|
WO/2015/044365A1 |
The invention provides a compound of the formula (1): or a salt or tautomer thereof, wherein either (i) R1 is hydroxy and R2 is hydrogen; or (ii) R1 and R2 are both fluorine; and R3 is hydroxy or a group that is convertible under physiol...
|
|
WO/2015/048558A1 |
This invention relates to antisense oligonucleotides comprising at least one N3'→P5' phosphorodiamidate linkage (NPN) in the backbone as well as methods for using the same. The antisense oligonucleotides can effectively prevent or decr...
|
|
WO/2015/041550A1 |
The subject matter of the invention is novel 2',5'-dideoxy-5-fluorouridine derivatives of general formula 1. (1) wherein R1 denotes cinchona alkaloid fragment with defined absolute configuration at C-8and C-9 atoms. In a second aspect, t...
|
|
WO/2015/042073A1 |
Provided herein is a method for synthesizing polynucleic acids, comprising the steps of (a) providing an acidic solution substantially free of nucleic acid polymerase and lipids, but containing mononucleotides and a monovalent salt; (b) ...
|
|
WO/2015/042447A1 |
Provided herein are compounds comprising one or more therapeutic nucleosides and one or more targeting groups. In certain embodiments, the compounds further comprise one or more oligonucleotides. In certain embodiments, a targeting group...
|
|
WO/2015/038596A1 |
This disclosure relates to nucleotide and nucleoside therapeutic compositions and uses in treating infectious diseases, viral infections, and cancer, where the base of the nucleotide or nucleoside contains at least one thiol, thione or t...
|
|
WO/2015/034420A1 |
The invention provides compounds of the formula:(I) wherein B is a nucleobase selected from the groups (a) to (d) and the other variables are as defined in the claims, which are of use in the treatment or prophylaxis of hepatitis C virus...
|
|
WO/2015/034038A1 |
[Problem] The purpose of the present invention is to develop a pharmaceutical composition that is for malignant tumor treatment and/or prevention and that by using a compound that is normally present in vivo and affects a cellular signal...
|
|
WO/2015/026845A2 |
Provided herein is technology relating to the manipulation and detection of nucleic acids, including but not limited to compositions, methods, and kits related to nucleotides comprising a chemically reactive linking moiety.
|
|
WO/2015/027137A1 |
Provided herein are compounds of Formula I, Formula II, and Formula X, which are useful for the treatment of infectious diseases. Also provided herein are processes for preparing 1-[5-0-[4,6-Dideoxy-6-oxo-6-[[[(3S)-hexahydro-2-oxo-1H-aze...
|
|
WO/2015/021432A1 |
Provided herein are analogs of unnatural nucleotides bearing predominantly hydrophobic nucleobase analogs that form unnatural base pairs during DNA polymerase- mediated replication of DNA or RNA polymerase-mediated transcription of RNA. ...
|
|
WO/2015/015517A1 |
The present invention provide water soluble polyfluorenes functionalized with glucuronic acid useful in sensing bilirubin in aqueous medium and process for preparation thereof. The invention further deals with detecting bilirubin in huma...
|
|
WO/2015/014722A1 |
The invention relates to methods of preparing nicotinamide riboside and derivatives thereof. In an aspect, the invention relates to a method of preparing a compound of formula (I), wherein n is 0 or 1; m is 0 or 1; Y is O or S; R1 is sel...
|
|
WO/2015/017713A1 |
Provided herein are compounds, compositions, and methods for the treatment of viral infections, for example, Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives ...
|
|
WO/2015/007291A1 |
The present invention relates to a novel alkaloid and novel bioactive alkaloid fractions derivable from Ribes preferably selected among Ribes Rubrum and Ribes nigrum; methods of manufacturing such bioactive Ribes alkaloid fractions and t...
|
|
WO/2015/003131A1 |
The present invention relates to substituted purine compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating disorders in which DOT1-mediated protein methylation play...
|
|
WO/2014/209983A1 |
Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are meth...
|
|
WO/2014/202493A1 |
The present invention is concerned with 2-oxo-2,3-dihydro-indoles of general formula (I) wherein Ar is a heteroaryl group, containing one, two or three heteroatoms, selected from N, S or O; R1 is hydrogen, lower alkyl, halogen, amino, di...
|
|
WO/2014/204861A1 |
The present invention provides a compound having the adenosylmethionine structure, wherein the sulfur atom of the methionine moiety is modified with alkene or succinimide groups, wherein R1, R2 and R3 are independently H, alkyl, aryl, C(...
|
|
WO/2014/194826A1 |
The present invention provides a three-circle fused-heterocycle nucleoside phosphoramidate compound, a preparation method therefor, a composition containing the fused-heterocycle nucleoside phosphoramidate compound, and an application of...
|
